Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCI vs MRI Surveillance in Limited-Stage SCLC
NCT05651802Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: 2-year brain metastasis-free survival. Started Jan 2023; status: recruiting.
Beyond the preview
Go deeper on NCT05651802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05651802.